12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Siponimod: Additional Phase II data

The double-blind, dose-ranging, international Phase II BOLD trial in 297 patients with RRMS showed that once-daily oral BAF312 met the primary endpoint by demonstrating a dose-response relationship in reducing the number of CUAL at 3 months (p=0.0001). Specifically, mean reductions in the number of CUAL from baseline to 3 months were 0.8 lesions for 0.25 mg BAF312, 1 lesion for 0.5 mg BAF312, 0.2 lesions for 1.25 mg BAF312, 0.5 lesions for 2 mg BAF312 and 0.4 lesions for 10 mg BAF312 vs. 1.5 lesions for placebo. Additionally, mean reductions in the number of CUAL from...

Read the full 459 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >